Literature DB >> 22574831

Stem/progenitor cells in non-lactating versus lactating equine mammary gland.

Jan H Spaas1, Koen Chiers, Leen Bussche, Christian Burvenich, Gerlinde R Van de Walle.   

Abstract

The mammary gland is a highly regenerative organ that can undergo multiple cycles of proliferation, lactation, and involution. Based on the facts that (i) mammary stem/progenitor cells (MaSC) are proposed to be the driving forces behind mammary growth and function and (ii) variation exists between mammalian species with regard to physiological and pathological functioning of this organ, we believe that studying MaSC from different mammals is of great comparative interest. Over the years, important data has been gathered on MaSC of men and mice, although knowledge on MaSC in other mammals remains limited. Therefore, the aim of this work was to isolate and characterize MaSC from the mammary gland of horses. Hereby, our salient findings were that the isolated equine cells met the 2 in vitro hallmark properties of stem cells, namely the ability to self-renew and to differentiate into multiple cell lineages. Moreover, the cells were immunophenotyped using markers for CD29, CD44, CD49f, and Ki67. Finally, we propose the mammosphere assay as a valuable in vitro assay to study MaSC during different physiological phases since it was observed that equine lactating mammary gland contains significantly more mammosphere-initiating cells than the inactive, nonlactating gland (a reflection of MaSC self-renewal) and, moreover, that these spheres were significantly larger in size upon initial cultivation (a reflection of progenitor cell proliferation). Taken together, this study not only extends the current knowledge of mammary gland biology, but also benefits the comparative approach to study and compare MaSC in different mammalian species.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574831     DOI: 10.1089/scd.2012.0042

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  7 in total

1.  Microvesicle-mediated Wnt/β-Catenin Signaling Promotes Interspecies Mammary Stem/Progenitor Cell Growth.

Authors:  Leen Bussche; Gat Rauner; Marc Antonyak; Bethany Syracuse; Melissa McDowell; Anthony M C Brown; Richard A Cerione; Gerlinde R Van de Walle
Journal:  J Biol Chem       Date:  2016-10-12       Impact factor: 5.157

2.  Comparative Analysis of microRNAs that Stratify in vitro Mammary stem and Progenitor Activity Reveals Functionality of Human miR-92b-3p.

Authors:  James L Miller; Matt Kanke; Gat Rauner; Kimaya M Bakhle; Praveen Sethupathy; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-10-03       Impact factor: 2.698

Review 3.  Mammary stem cell research in veterinary science: an update.

Authors:  Bizunesh M Borena; Leen Bussche; Christian Burvenich; Luc Duchateau; Gerlinde R Van de Walle
Journal:  Stem Cells Dev       Date:  2013-03-05       Impact factor: 3.272

Review 4.  Beyond tradition and convention: benefits of non-traditional model organisms in cancer research.

Authors:  Rebecca M Harman; Sanjna P Das; Arianna P Bartlett; Gat Rauner; Leanne R Donahue; Gerlinde R Van de Walle
Journal:  Cancer Metastasis Rev       Date:  2020-10-28       Impact factor: 9.264

5.  Differential signaling pathway activation in 7,12-dimethylbenz[a] anthracene (DMBA)-treated mammary stem/progenitor cells from species with varying mammary cancer incidence.

Authors:  Melissa M Ledet; Meghan Oswald; Robyn Anderson; Gerlinde R Van de Walle
Journal:  Oncotarget       Date:  2018-08-28

6.  Secreted sphingomyelins modulate low mammary cancer incidence observed in certain mammals.

Authors:  Melissa M Ledet; Rebecca M Harman; Jennifer C Fan; Emily Schmitt-Matzen; Maria Elena Diaz-Rubio; Sheng Zhang; Gerlinde R Van de Walle
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

Review 7.  Development and Pathology of the Equine Mammary Gland.

Authors:  Katherine Hughes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-12-05       Impact factor: 2.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.